Fig. 5: SGLT1 expression negatively correlates with the clinical benefits of EGFR TKI in NSCLC patients.
From: PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs
a, b Tumor tissues from total NSCLC patients ever treated with EGFR TKIs were subjected to IHC staining with anti-SGLT1 antibody ((a) upper). Scale bar, 50 μm. The clinical correlation of SGLT1 expression with overall survival (a) and progression-free survival (PFS) (b) rates were analyzed in Kaplan–Meier analysis. c–f The EGFR TKI-treated NSCLC patients in (a and b) were further classified into wt EGFR (c) and (d) and mutant EGFR (e) and (f) groups for Kaplan–Meier overall survival and progression-free survival analysis. g, h SGLT1 protein levels in the paired tissues from treatment-naïve tumors and acquired TKI-resistant tumors of nine lung cancer patients were examined by IHC staining (upper in panel (g)) and quantitated (lower in panel (g)). The results from panel (g) were further divided into two groups according to the genders of patients (h). Scale bar, 50 μm.
